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ABSTRACT 
Objective: Azithromycin (AZM), an azalide drug is used to treat bacterial infections. It is poorly water-soluble, with low human bioavailability due 
to partial absorption. This can be improved using a microemulsion drug delivery system using essential oil. 
Methods: Microemulsion system was prepared with AZM solubilized lemongrass oil (Cymbopogon citratus), Tween 20 and water containing 1% 
(v/v) 10 mmol sodium hydroxide. In vitro drug release was determined using a 14KDa semipermeable dialysis membrane. The kinetics of bacterial 
killing was done at MIC concentrations, and viable counts were determined hourly for 24 h. Bacterial cell viability was determined by differential 
staining with acridine orange and ethidium bromide. In vitro toxicity was determined by the MTT assay, while in vivo toxicity was determined in 
male Wistar rats. 
Results: The optimized formulation (5:20:75 %) was thermodynamically stable with drug solubility of 366.90 mg/ml and a droplet diameter of 
12.4±3.9 nm, which do not show in vivo or in vitro toxicity. In vitro drug release study in simulated body fluids revealed a controlled drug release 
from microemulsion-based formulation. The MIC was 1μg/ml and 2μg/ml against Staphylococcus aureus and Escherichia coli respectively. In vitro 
kill kinetics showed>2 log10
Conclusion: The reduced droplet size and the inherent antibacterial property of lemongrass oil enhanced the efficacy of the AZM loaded ME system 
in comparison with the bulk drug, against the bacterial pathogens. 
 killing by 8 h. Bacterial cell viability assay and scanning electron microscopy analysis further confirmed substantial 
morphological changes due to alteration in the cell membrane. 
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Most of the new drugs currently in use are hydrophobic in nature 
[1], and their oral delivery is hindered by low oral bioavailability, 
lack of dose proportionality, high intra-and inter-subject variability, 
and short shelf life [2]. Recently, more attention is focused on oil-
based or lipid-based formulations with a focus on self-micro 
emulsifying drug delivery system (SMEDDS) to improve these issues. 
SMEDDS, also termed as microemulsion (ME), are isotropic mixtures 
of essential oils and surfactants, with or without co-surfactants, 
which emulsify spontaneously or with gentle agitation on hydration 
to produce a transparent and homogeneous microemulsion [3, 4]. 
They are thermodynamically stable, isotropic, clear dispersion, with 
high stability, low interfacial tension, and low viscosity [5]. Major 
advantage of ME includes improvement in drug solubility, 
enhancement of bioavailability, improvement in drug stability and 
prolonged shelf life [6].  
This study describes the formulation and characterization of an oil-
in-water ME using lemongrass (Cymbopogon citratus, Family: 
Poaceae) oil (LG), a non-ionic surfactant and water. The main active 
components of LG oil for an aroma and taste are citral (65–86%) [7], 
neral and geraniol. Each component has significant medicinal 
properties such as antidepressant, analgesic, antimicrobial [8], 
antiseptic, antipyretic, astringent, carminative, diuretic, deodorant, 
febrifuge, galactagogic, nervine, insecticidal and sedative [9, 10]. 
Azithromycin (AZM), an azalide antibiotic has its antibacterial 
activity due to a 15-membered aglycone ring with an additional 
nitrogen molecule [11]. It binds to a 50S subunit of the 70S bacterial 
ribosome and interferes with the elongation of the nascent 
polypeptide chain, which inhibits the RNA dependent protein 
synthesis in susceptible micro-organisms [12]. AZM is highly 
lipophilic and has a low oral bioavailability of 37%. Acid degradation 
of the drug before absorption and possibly, incomplete absorption 
accounts for low bioavailability [13]. Hence, these limitations 
necessitates the need to improve the formulation by designing a 
more effective drug delivery system for AZM. 
Hence, the aim of the study was to develop an AZM loaded LG oil-in-
water (o/w) emulsion for improved delivery and efficacy of 
azithromycin. 
MATERIALS AND METHODS 
Materials 
Azithromycin (AZM) was received from Aurobindo Pharma Limited, 
Hyderabad, India. Pure essential oil of lemongrass obtained from 
Falcon essential oils, Bengaluru, India. Tween 20 (Polyethylene glycol 
sorbitan monolaurate), and Tween 80 (Polyethylene glycol sorbitan 
monooleate) were obtained from Sigma–Aldrich, Bengaluru, India. 
Span 20, Span 80, Cremophor EL, brain heart infusion agar, Mueller 
Hinton agar, Staphylococcus aureus (ATCC 25923) and Escherichia coli 
(ATCC 25922) were obtained from Himedia laboratories private Ltd, 
Chennai, India. Sodium hydroxide pellets (NaOH) obtained from SRL 
private limited, Mumbai, India. For all experiments, ultrapure water 
(Cascada Biowater System, USA) with a resistivity of not less than 
18.2MΩ/cm was used. All other reagents used were of analytical grade. 
Solubility study 
The drug solubility of AZM was determined in various oils and 
surfactants (table 1) by the equilibration method. An excess 
amount of drug was added to 1 ml of the selected oil or surfactant 
and vortexed to facilitate the solubilization. The vials were sealed 
and kept in an orbital shaker (Orbitek, Scigenics Biotech, India) for 
72 h at 24±1 °C to attain equilibrium. Each vial was centrifuged at 
600 x g for 15 min, and the drug-saturated supernatant was 
filtered through a 0.45 μm membrane filter. The final 
concentration of the drug in the filtrate was determined using a 
UV–visible spectrophotometer (U2910, Hitachi, Japan) after 
appropriate dilution with carbinol [14, 15]. 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 10, Issue 6, 2018 
Chandrasekaran et al. 
Int J App Pharm, Vol 10, Issue 6, 2018, 72-81 
 
73 
Selection of surfactant 
The surfactant used for the preparation of ME formulation depends 
on its hydrophilic-lipophilic balance (HLB) value and non-toxic 
nature. Non-ionic surfactants like polysorbates (Tween 20, Tween 
80), sorbitan esters (Span 20, Span 80), and Cremophor EL were 
chosen. These surfactants were examined for highest emulsification 
efficiency with the selected oil showing maximum solubility. 
Selection of surfactant was made on the basis of percentage 
transparency and ease of emulsification. An equal amount of each 
surfactant and LG oil was mixed individually. The mixture was 
gently heated to 45-50 °C to attain homogenization. 100l of each 
mixture was diluted in 50 ml ultrapure water in a separate glass 
stoppered conical flask. The level of emulsification was determined 
by counting the required number of flask inversions to give a clear 
homogeneous emulsion by observing visually. The percentage 
transparency (%) of the resulting emulsions were examined at 600 
nm by a UV spectrophotometer taking ultrapure water as a blank 
and reference [16]. The surfactant producing a clear emulsion with 
the least number of inversions and maximum transparency was 
selected for the further analysis. 
Pseudo-ternary phase diagram 
Two groups of oil and surfactant mixture with different 
combinations were determined, and the pseudo-ternary phase 
diagram was made using the water titration method according to 
Syed HK et al [17]. The first group contains combination of oil and 
surfactant mixture ratios as 1:1,1:2,1:3,1:4,1:5,1:6,1:7,1:8 and 1:9 
(v/v), and another group of combination contain 1:9, 2:8, 3:7, 4:6, 
5:5, 6:4, 7:3, 8:2 and 9:1 (v/v). Ultrapure water was added gradually 
to each mixture and visual transformation of the sample from turbid 
to transparent and reverse was noticed to determine the phase 
appearance. The areas and boundaries at which the clear and 
transparent microemulsion domains obtained from the endpoint 
composition of the titrated samples were determined with the aid of 
plotting the pseudo-ternary phase diagram, using Origin Pro 8.5.0 
(Origin Lab Corporation, USA). Experiments were performed in 
triplicate, to confirm reproducibility [15]. 
Preparation of Microemulsion 
The clear monophasic region plotted in phase diagram delineates 
the ME domain. The ratio at which the transparent and clear 
formulation obtained with minimal surfactant concentration was 
identified [18]. 1% (w/v) Azithromycin (AZM), solubilized in LG oil 
was used to prepare the drug-loaded ME formulation (LGME-AZM) 
with the optimized ratio obtained from the preliminary study. To 
study the phase behavior of the ME region, two group of 
formulations were prepared with different oil to surfactant ratios, 
making up to 100% with an aqueous phase containing water with 
1% (v/v) 10 mmol NaOH [19]. Visual appearance of the obtained 
formulations with a change from turbid to translucent was observed.  
Thermodynamic stability study 
The thermodynamic stability of LGME-AZM formulations that appears 
transparent visually was examined under the extreme stress conditions 
[20]. Centrifugation was done at 1500 x g for 30 min to ensure physical 
stability. The stable, transparent formulations were cooled to 4 °C 
alternating with heating at 45 °C for 48 h at each temperature, repeated 
for six cycles. The formulations that remain stable were then subjected to 
freeze-thaw conditions. Here, the formulations were taken on to three 
cycles of −21 °C and+25 °C for 48 h each. The formulations that remain 
transparent with no phase separation were taken for further 
characterization [15].  
Characterization of optimized ME 
Characterization of all samples was performed in triplicate. 
Experiments were performed at 25±1 °C and results were 
represented as mean±SD. 
(a) pH measurement 
The pH value of thermodynamically stable, clear and transparent 
formulation was determined using a calibrated pH meter 
(Systronics, India). 
(b) Conductivity measurement 
Electrical conductivity (σ) was a reliable and convenient method to 
investigate the structural features of ME. The conductivity 
measurement helps in determining the nature of the continuous 
phase of the ME system [21]. The electro-conductivity (σ) of the 
formulated sample was evaluated using a conductivity meter (CM 
180, Elico, India). 
(c) Turbidity determination 
The turbidity of the translucent formulations were analyzed by 
measuring the absorbance at a visible wavelength (600 nm) using a 
UV–visible spectrophotometer with ultrapure water as blank and 
reference. 
(d) Viscosity determination 
The viscosity reading was measured using a spindle viscometer 
(DV3TLVT, Brookfield Inc., USA) equipped with spindle no. 18. 
Size analysis 
(a) Droplet size determination 
The ME droplet size and the polydispersity index (PI) was analyzed 
by dynamic light scattering (DLS) technique using nanoparticle 
analyzer (SZ-100 Horiba, Japan). The particle size of the optimized 
LGME-AZM formulation was determined using a diode pumped 
frequency double laser at 532 nm (10 mW) light scattering at an 
angle of 173°. Data acquisition and analysis was performed using the 
software provided by the manufacturer. 
(b) Zeta potential determination 
To determine zeta potential, the transparent ME was analyzed using 
a nanoparticle analyzer. This analysis was based on the 
electrophoretic mobility (cm2
In vitro release studies  
/V-s) of the particles, that gets 
converted to as zeta potential (mV), which was measured using the 
software provided. 
The in vitro drug release of AZM from the optimized LGME-AZM was 
performed by diffusion study using dialysis membrane and the 
diffusion medium containing simulated body fluids, prepared 
according to U. S. Pharmacopeia (USP) [22]. Dialysis membrane was 
filled with LGME-AZM (equivalent to 2 mg AZM) and AZM bulk drug 
suspension (2 mg) separately, and the ends were sealed. Both of these 
dialysis bags were immersed into 180 ml of simulated gastric fluid (pH 
1.2), and simulated intestinal fluid (pH 6.8), at 37±1 °C with a 50 rpm 
rotating speed. Sample (1 ml) was withdrawn at regular time intervals 
(1-8 h), and an equal volume of the respective fluid was added to 
uphold the constant volume. The sample withdrawn was filtered using 
a 0.45 𝜇𝜇m filter and the amount of drug release at each time interval 
was determined using UV visible spectrophotometric method [23]. All 
the experimental readings were noted in triplicate. 
Antibacterial activity 
(a) Bacterial inoculum 
The antibacterial activity of LGME-AZM was assessed against 
Staphylococcus aureus ATCC 25923 and Escherichia coli ATCC 25922, 
preserved at-80 °C in brain heart infusion (BHI) broth with 10% 
(v/v) glycerol. The bacterial cultures were revived onto BHI agar 
plates at 37±1 °C incubated overnight, and the bacterial colonies 
grown were suspended in sterile physiological saline (0.85% NaCl), 
to obtain culture suspensions for the anti-bacterial studies.  
(b)Minimum inhibitory concentration (MIC) determination 
using resazurin assay 
The MIC value of the LGME-AZM against S. aureus and E. coli was 
determined using resazurin-microtiter plate method (96-well plate 
technique) with slight modification as reported earlier in Elshikh et 
al., 2016 [24]. This method was adopted owing to its precise and 
sensitive results to compare the earlier results. The MIC was 
determined according to the clinical and laboratory standards 
institute (CLSI) protocols [25]. Resazurin was prepared at 0.015% 
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(w/v), filter sterilized (0.45 µm filter) and stored at 4 °C. After 
overnight incubation at 37±1 °C, 10% (v/v) of prepared resazurin 
dye was added to each well and incubated at 37±1 °C for 2 h. The 
change in color from blue to pink was observed. The lowest 
concentration is showing the complete absence of pink color was 
expressed as the MIC of the tested sample against the particular 
strain and expressed in µg/ml [24, 26]. 
Time-kill assay 
Time-Kill assay also known as the suspension time-kill analysis 
determines the in vitro antimicrobial activity of the test sample in 
relation to time. AZM bulk suspension and LGME-AZM were tested 
against each bacterial strain (inocula similar to MIC inocula) at 0.5x, 
1x and 5x MIC. The viability of treated strains and suitable controls 
were determined by dilution and plating onto sterile BHI Brain heart 
infusion (BHI) agar plates incubated overnight at 37±1 °C. 
(c) Determination of cell viability 
The cell viability assay was performed using acridine orange (AO) and 
ethidium bromide (EtBr) double staining method to distinguish the live 
and dead bacterial cells after treatment [27]. The level of membrane 
disintegration of S. aureus and E. coli after being treated with 1x MIC of 
LGME-AZM was observed under fluorescent microscopy. The culture 
inoculum (1x108 CFU/ml) interacted with the 1x MIC of the test sample 
prepared accordingly with phosphate buffer saline (PBS). The treated 
bacterial cultures were washed with PBS by centrifugation to obtain a 
pellet. 4 µl each of AO (15 µg·ml-1 in PBS) and EtBr (50 µg·ml-1 in PBS) 
stain was added to the pellet, vortexed and kept for incubation, for 10 
min. The unbound dyes were removed after centrifugation and pellet 
was re-suspended in PBS. The images were analyzed and captured using 
fluorescence microscope (DM-2500, Leica Microsystems, USA) equipped 
with a digital camera (DFC-295, Leica Microsystems, USA) and processed 
with Leica Application Suite 3.8 [15]. 
(d) Scanning electron microscopy (SEM) 
The bacterial cell suspension of both bacterial strains (S. aureus and E. 
coli) at 1x108 CFU/ml in PBS was treated with LGME-AZM at 1x MIC for 
18 h. Untreated bacterial suspensions were used as negative controls. 
The cells were harvested by centrifuging at 2000 x g for 10 min. The cells 
in the pellet were coated onto a glass slide (1 cm2
Fresh blood was collected in the heparinized tube from a healthy 
human donors (n=6), according to the institutional guidelines, with 
the reference number VIT/IECH/014/Jan24.2015. Lymphocytes, a 
peripheral blood mononuclear cell (PBMC) were separated using 
lymphocyte separation media (HiSep™, HiMedia, India) by density 
gradient separation technique [29]. Isolated lymphocytes were re-
suspended in RPMI 1640 media and stored at 4 °C. The human 
lymphocytes (1×10
), air dried and dipped 
in 2.5% glutaraldehyde for 2 h to fix the cells. Further, the cells were 
dehydrated in a solution containing increasing concentrations of ethanol 
(30%, 50%, 70%, and 99.9%) for 10 min each [28]. The process of 
sputter coating with an ultra-thin electrically conducting metal, 
gold/palladium (Au/Pd) was placed onto the specimen on a glass slide, 
prior to SEM imaging. The surface morphology of the samples was 
observed under high-resolution SEM (EVO18 Research, Zeiss, Germany). 
Toxicity studies 
(a) In vitro toxicity testing 
4 cells/ml) in RPMI 1640 was treated with 
optimized LGME system and LGME-AZM; and also with the 
individual components (LG oil, Tween 20) at various concentrations 
(50%, 25%, and 12.5%). These were incubated overnight at 37±0.5 
°C with 5% CO2
(b) In vivo acute and sub-acute toxicity testing 
. About 20 µl per well of 0.5 % (w/v) MTT solution 
was mixed with the treated cells and incubated at 37±1 °C for 4 h. 
After incubation, 50 µl of dimethyl sulfoxide (DMSO) was added, and 
the absorbance reading was measured using PowerWave XS2 
microplate reader (BioTek Corp, USA) at a visible wavelength. The 
percentage of cell viability was represented as mean±SD [30] 
Animal studies were done to determine the in vivo toxicity testing of the 
novel drug formulation. Ethical approval (VIT/IAEC/10th/March 
14th/No.04) was obtained from the Institutional Animal Ethical 
Committee (IAEC, VIT Vellore) following guidelines of Committee for the 
Purpose of Control and Supervision of Experiments on Animals (CPCSEA, 
India). The study was done to assess the toxicity of drug loaded ME by 
acute and sub-acute toxicity in male Wistar rats according to the 
Organisation for Economic Co-operation and Development (OECD) 
guidelines 423 and 407. This testing includes analysis for biochemical 
markers, hematological and histopathological changes observed due to 
oral administration. Before experimentation, Wistar rats (4-6 w) were 
provided with food and water ad libitum and housed at 26±2 °C in the 
animal house for acclimatization for 1 w. Rats were divided into three 
groups (n=6 per group) as LGME system, LGME-AZM, and healthy 
control group respectively. About 1 ml/kg body weight of the respective 
test samples were administered orally by oral gavage, except to the 
healthy control group. After the final administration, animals were 
weighed and euthanized by asphyxiation with CO2
RESULTS AND DISCUSSION 
 gas. Blood sample 
withdrawn and serum/plasma was separated. Complete blood count 
(CBC) was analyzed. Blood enzymes such as aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) was measured to assess the 
liver function, and creatinine was measured for kidney function evaluation 
[31]. Dissection procedure was done, and the organs such as liver and 
small intestine were removed, and fixed in 10% buffered formalin solution 
for histopathological studies. Tissue sections (6 µm) were sectioned, 
stained with hematoxylin-eosin (HandE), and visualized under an optical 
microscope to study the hepatotoxicity and nephrotoxicity. 
Statistical analysis 
All experiments were performed in triplicate and results 
represented as mean±SD. All calculations and graphs were drawn 
using Microsoft Excel 2016 (Microsoft Corporation, USA). 
Selection of components 
To develop a biocompatible oral drug delivery system for AZM, varied 
components were picked from the generally regarded as safe (GRAS) 
category. Favorably, the oil-in-water ME acts as a major vehicle in the 
incorporation of the hydrophobic drug, which thus leads to improved 
solubility, maintains stability and exhibits an improved drug diffusion 
in vivo [15]. The oil system in ME helps in drug maintenance in its 
solubilized form. The solubility of AZM in varied oils and surfactants 
were depicted in table 1. Based on the maximal solubility of AZM in 
lemongrass oil (366.90 mg/ml), this was preferred as the relevant oil 
system for the preparation of ME formulation. 
  
Table 1: Solubility of azithromycin in oils and surfactants 





Cremophor EL 31.73±0.42 
Tween 20 8.17±0.13 





(* Values with mean±SD, n = 3) 
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Selection of surfactant 
Non-ionic surfactants including polysorbates (Tween 20, Tween 80), 
sorbitan esters (Span 20, Span 80), and cremophor EL were 
screened for higher emulsification efficiency. Tween 20 showed 
highest emulsification efficiency for lemongrass oil, with maximum 
transparency and least number of flask inversions in comparison 
with the other surfactants as shown in table 2. Non-ionic surfactants, 
especially tween 20 and tween 80 were most commonly used to 
diffuse hydrophobic particles in aqueous solutions. As tween 20 
shows maximum emulsification with LG oil, it was preferred to use 
in preparation of oil-in-water ME. Existing research favouring tween 
20 in drug delivery system explains the surfactant as more 
biocompatible, minimally toxic, less haemolytic and reduced level of 
irritation to cellular surfaces and able to maintain physiological pH 
in solutions [32, 33]. 
 
Table 2: Emulsification efficiency of surfactants 
Surfactant % Transparency No. of inversions* * 
Tween 20 99.98 02 
Tween 80 98.98 04 
Span 20 99.83 20 
Span 80 99.80 20 
Cremophor EL 99.98 09 
*
 
Pseudo-ternary phase diagram 
 Values with mean (n=3) 
Pseudo-ternary phase diagram was constructed using water 
titration method to describe the region of clear microemulsions and 
provide a greater understanding on the relation between phase 
behavior of the emulsion and its varying compositions. A pseudo-
ternary phase diagram of the investigated ternary system LG 
oil/Tween 20/water was plotted (fig. 1). Formation of visually 
transparent ME system (black spotted points) was observed at room 
temperature. Phase behavior determination was indicated as the 
suitable approach to determine the oil phase, surfactant and 
aqueous phase concentration, with which the transparent, 
homogenous, and low-viscous ME system was formed. This plotting 
reveals the possibility of ratios at which the maximum proportion of 
oil was incorporated with less composition of surfactant (<50%) to 
give the homogenous ME systems [34]. 
 
 
Fig. 1: Pseudo-ternary phase diagrams done with lemongrass oil/tween 20/water. (a) ME transparent region between oil and surfactant 
ratio 1:1 to 1:9 (b) ME transparent region between oil and surfactant ratio 1:9 to 9:1 
 
Optimization of the drug loaded microemulsion 
The phase study reveals the maximum proportion of oil with a 
minimal concentration of surfactant to give a monophasic clear ME. 
The higher oil content in ME may provide an ability to incorporate a 
larger quantity of AZM. Moreover, when the percentage of surfactant 
in a ME preparation was<50%, the formulation was less viscous and 
minimizes the toxicity. According to these phenomena, the 
formulation showing transparent ME containing LG oil (5%), tween 
20 (20%), and water (75%) was chosen from the phase study. Fig. 2 
shows the visual appearance of all the formulations with LG 
oil/tween 20/water. It was necessary to determine the lowest 
concentration of surfactant (Tween 20) to form a clear homogenous 
formulation. The concentration of oil and water was kept constant 
respectively in each set of formulations prepared as shown (fig. 2a 
and 2b). The pH of formulations ranged between 4.8 and 5.8. As this 
might affect drug absorption in oral drug delivery, 1% of 10 mmol 
NaOH was added to the aqueous phase of the optimized ME to 
maintain a neutral pH. The visual inspection of both sets of 
formulations shows that the formulation with higher interfacial 
tension shows a phase separation, with milky white to turbid 
denoted a biphasic region [15]. Whereas the formulations with less 
or reduced interfacial tension, as there was an increase in surfactant 
concentration showed transparent homogeneous formulations with 
no phase separation, which signifies the presence of an ME region. 
The clear and transparent formulations, 1:4 to 1:9 in 1st set and 1:9 
to 4:7 in the 2nd
 
 set were subjected to accelerated thermodynamic 
stability tests to determine the optimized ME ratio. 
 
Fig. 2: Visual appearance of formulations from lemongrass 
oil/tween 20/water: Formulations with LG oil: surfactant ratio 
(a) 1:1 to 1:9 (b) 1:9 to 9:1 
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Thermodynamic stability study 
All the transparent AZM loaded formulations were found to be physically 
stable (table 3 and table 4), except the formulations (1:3 and 4:6), which 
lost their stability and became turbid during the heating cycle. The 
transparent formulation (1:4) was formed with a minimal surfactant 
concentration and contain adequate oil concentration to solubilize drug. 
From this criterion, the optimized formulation of LGME-AZM (1:4) was 
determined to be with a LG oil/tween 20/water ratio of 5:20:75 %. This 
optimized formulation of AZM was thermodynamically stable. 
  
Table 3: Observations of the thermodynamic stability tests of formulations with lemongrass oil/tween 20 ratio (1:1 to 1:9) 
O/S Ratio O: S: W (%) CENTRF Heating /Cooling Freeze /Thaw 
1:1 5:5:90 X x X 
1:2 5:10:85 X x X 
1:3 5:15:80 Clear Turbid X 
1:4 5:20:75 Clear Clear Clear 
1:5 5:25:70 Clear Clear Clear 
1:6 5:30:65 Clear Clear Clear 
1:7 5:35:60 Clear Clear Clear 
1:8 5:40:55 Clear Clear Clear 
1:9 5:45:50 Clear Clear Clear 
(O-Lemongrass oil, S-Surfactant, W-Water, CENTRF-Centrifugation) 
 
Table 4: Observations of the thermodynamic stability tests of formulations with lemongrass oil/tween 20 ratio (1:9 to 9:1) 
O/S Ratio O: S: W (%) CENTRF Heating /Cooling Freeze /Thaw 
1:9 5:45:50 Clear Clear Clear 
2:8 10:40:50 Clear Clear Clear 
3:7 15:35:50 Clear Clear Clear 
4:6 20:30:50 Clear Turbid x 
5:5 25:25:50 x x x 
6:4 30:20:50 x x x 
7:3 35:15:50 x x x 
8:2 40:10:50 x x x 
9:1 45:5:50 x x x 
(O-Lemongrass oil, S-Surfactant, W-Water, CENTRF-Centrifugation) 
 
Physicochemical characterization 
(a) pH, conductivity, turbidity and viscosity measurement 
The pH of the optimized thermodynamically stable LGME-AZM (1:4) 
was found to be 6.54±0.005. The pH did not vary significantly with 
storage due to the presence of non-ionic surfactant in the system. Its 
electrical conductivity (σ) was 0.274±0.001 μS/cm. The higher water 
concentration (75% v/v) showed an increase in electrical 
conductivity, which clearly confirms the oil-in-water nature of the 
ME. Quantitative measurement of the optical transparency of 
optimized LGME-AZM in the visible wavelength (600 nm) shows 
absorbance of less than 0.010±0.001. The percent transmission was 
found to be more than 90% which confirms the homogenous nature 
of ME. The viscosity determination on the drug-loaded formulations 
was observed to be very low (5.69cP±0.20), due to the homogeneous 
nature of ME [35]. 
Size analysis 
(a) Droplet size interpretation 
The principle of DLS analysis was based on the particle diffusion due 
to Brownian motion, gives the basic detail of the particle size [36]. 
The DLS technique was appropriate to study the colloidal 
dispersions. The mean droplet size of the optimized LGME-AZM 
(1:4) was 12.4±3.9 nm (fig. 3). Smaller droplet size of the drug-
loaded ME has vital importance in drug delivery system, as this 
determines the degree and intensity of drug release, which was 
directly related to the drug absorption [16]. The polydispersity 
index (PDI) illustrates the quality or homogeneity of the dispersion 
[37]. The mean PDI of LGME-AZM (1:4) formulation was 0.4±0.001. 
This result shows that the formulation with a very low PDI 
illustrates the homogeneous size distribution of the droplets. This 
clearly explains that the particle distribution was one of the 
mechanisms that controls the stability of the ME, as the uniform 
distribution of ME droplets provides better stability [15]. 
 
Fig. 3: Droplet size analysis of optimized LGME-AZM (1:4) 
 
(b) Zeta potential measurement 
The droplets or particles in an emulsion carries an electrical charge. 
Zeta (ζ) potential was explained as the difference in potential 
between the tight bound layer of the droplets surface and the 
electroneutral region of an emulsion [38]. The zeta potential of the 
optimized LGME-AZM (1:4) formulation was found to be-13.9±0.42 
mV. The amount of charge on the particle surface was an important 
characteristic to determine the stability of an emulsion, as ζ-
potential controls, the extent of repulsion between the adjacent, 
similarly charged, dispersed droplets. The decrease in ζ-potential 
induces the attractive forces to exceed the repulsive force, which 
might lead to the aggregation of droplets [39]. 
In vitro release studies 
In vitro drug release from LGME-AZM and AZM bulk drug suspension 
was done by dialysis method using dialysis membrane. The amount of 
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drug release obtained by the dialysis method provides an indirect 
correlation with the in vivo drug release [40]. The in vitro release 
action of the LGME-AZM and AZM bulk drug suspension was 
summarized as cumulative percentage release as shown in fig. 4. In 
simulated intestinal fluid after 8 h, about 64.79±1.61 % of the drug 
was released in case of LGME-AZM, while pure AZM drug showed only 
18.74±0.49% of diffusion profile. In the same way, in the case of 
simulated gastric fluid after 8 h, about 36.2±1.95 % of the drug was 
released in case of LGME-AZM, while plain drug showed only 
7.08±0.16 % of diffusion. The release studies were conducted for 8 h to 
observe the deviation or existence of precipitation over time. The in 
vitro drug release studies indicate that the formulation of AZM in the 
form of LGME-AZM formulation enhances the drug diffusion 
properties. It was observed that the total percentage of drug diffusion 
was much higher in ME system than pure drug suspension in both 
simulated body fluids. The drug diffusion from ME was observed to be 
higher in the intestinal fluid than the gastric fluid, which explains to be 
advantageous for increased drug absorption [41]. 
 
 
Fig. 4: Cumulative drug release (%) of LGME-AZM and AZM pure drug suspension in relevant dissolution medium (a) Simulated intestinal 
fluid (b) Simulated gastric fluid 
 
Antibacterial activity 
Minimum inhibitory concentration (MIC)  
Resazurin micro titre plate method was done to determine the 
minimum inhibitory concentration. The antimicrobial activity of both 
optimized LGME-AZM and AZM bulk drug suspension was assessed 
against two bacterial strains, S. aureus, and E. coli. The MIC value was 
read by visual observation in a change of colour in the wells. At higher 
concentrations of drug interaction with bacterial strains, blue 
coloration was observed to indicate that all microbial cells were killed 
or inhibited. At lower concentrations of the drug, the wells appear 
pinkish, which indicates the growth of the microbial culture. The least 
or minimum concentration that inhibited or killed the microbial 
growth (blue colour) was considered as the MIC (µg/ml) value for the 
tested compounds, respectively. In the case of S. aureus, the MIC value 
of AZM bulk drug suspension and LGME-AZM was found as 4 μg/ml 
and 1 μg/ml respectively. For E. coli, the inhibition for AZM bulk drug 
suspension and LGME-AZM was found to be 4 μg/ml and 2 μg/ml 
respectively. From the results obtained, it clearly states that the 
optimized LGME-AZM formulation showed two-fold increase in 
antibacterial activity against S. aureus and a single fold increase for E. 
coli, in comparison with the conventional pure AZM drug.  
Time-Kill kinetics assay 
The resulting data for the Time Kill assay was typically 
presented graphically (fig. 5), where the colony counts for each 
antimicrobial agent was plotted against the concentration tested 
at each time point (0-8 h). The optimized LGME-AZM and AZM 
bulk drug suspension was tested at 0.5x, 1x and 5x of its MIC 
obtained from the previous study. Here, the viable colony counts 
(CFU/ml) was observed at each time interval with each 
concentration. Fig. 5 clearly shows that the LGME-AZM at 1x and 
5x MIC was able to decrease the viable counts of both bacterial 
strains, S. aureus, and E. coli by>2log10 
  
within 8 h. It explains that 
the bacterial strains were more susceptible to the optimized 
LGME-AZM at 1x and 5x MIC in comparison with the AZM bulk 
drug form at the same MIC. 5x MIC of LGME-AZM acts completely 
bactericidal by 8 h. At higher MIC, ME acts as bactericidal; 
whereas in reduced MIC, enhanced growth was observed. Based 
on the mechanism of action, protein synthesis inhibitors such as 
macrolides (AZM) are considered as bacteriostatic agents, which 
suppresses bacterial growth. Bacterial strains that are exposed 
to those antibiotics at the MIC or higher can grow again after 
antibiotic elimination [42]. 
 
Fig. 5: Time-kill kinetics of LGME-AZM (1:4) and AZM pure drug suspension against S. aureus and E. coli 
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Determination of cell viability  
The cell viability or morphological alterations in the cell membrane 
of the treated bacteria was validated using AO and EtBr staining 
assay. Necrotic and apoptotic cells were differentiated from normal 
live bacteria cells using these dyes under fluorescent microscopy. AO 
is a basic dye that stains both live and dead cells, whereas EtBr will 
stain only the bacterial cells which loses its membrane integrity [15]. 
Untreated bacterial live cells of S. aureus (fig. 6a) and E. coli (fig. 6b) 
appears fluorescent green in color, which illustrates the staining 
with AO. After the interaction of bacterial strains with 1x LGME-
AZM, it appears red in color (fig. 6c and fig. 6d). The prepared slides 
were observed under a fluorescence microscope at 100X 
magnification. This signifies the antibacterial activity of the 
optimized ME formulation with AZM in damaging the bacterial cell 
membrane, which in turn leads to cell death. The ME droplet has the 
capability to fuse with lipid bilayer in the cell membrane of the 
bacterial pathogens and disrupts the cell membrane, and thereby 
impair the membrane integrity [43]. This causes lysis and death of 
the cell treated with ME. The alterations in the cell membrane 
changes the permeability and lead to the subsequent release of the 
intracellular components [44]. 
 
 
Fig. 6: Fluorescent micrographs of AO and EtBr double-stained bacterial strains to access the cell viability (i) Bacterial strains without 
treatment (control): (a) S. aureus, and (b) E. coli. (ii) Bacterial strains treated with 1x MIC of LGME-AZM (1:4) (c) S. aureus (d) E. coli 
 
Cell damage study by SEM 
Visual assessment of cell damage to bacteria provides definitive 
evidence to the antibacterial activity of the ME formulation against 
pathogenic bacterial strains. Bacterial cells treated with LGME-AZM at 
1x MIC demonstrated considerable morphological changes in the cell 
structure compared to the untreated bacterial strain observed under a 
scanning electron microscope (SEM). The treated cells of S. aureus and 
E. coli showed morphological changes in comparison to the untreated 
cells. The morphology of control cells of S. aureus and E. coli was 
smooth, with intact cell membrane (fig. 7a and 7c). After exposure to 
the optimized LGME-AZM, the cells were remarkably deteriorated, 
showing an irregularity in shape and structure of the cells (fig. 7b and 
7d). This clearly explains the leakage of the cytoplasmic material of the 
bacterial cells. Tyagi et al. observed that E. coli treated with LG oil 
showed aggregation and deformities [45]. Korenblum et al. also stated 
that both LG oil and its major component, citral showed an immediate 
killing effect against sulfate reducing bacteria, suggesting that citral 
was responsible for the antibacterial activity of LG oil [46]. The SEM 
micrographs explains that the LGME-AZM formulation in comparison 
with the pure drug AZM has an enhanced antibacterial property 
against pathogenic bacterial strains. 
 
 
Fig. 7: SEM images: (i) S. aureus-(a) Untreated control (b) Treated with 1x MIC of LGME-AZM (1:4); (ii) E. coli.-(c) Untreated control and (d) 
Treated with 1x MIC of LGME-AZM (1:4). Magnification at 18KX for S. aureus and 34KX for E. coli 
Chandrasekaran et al. 




(a) In vitro toxicity testing 
PBMC’s have a major role in human defense mechanism. They are 
nucleated cells, consist of lymphocytes and monocytes. The cultured 
lymphocytes were isolated to analyse the in vitro toxicity estimation 
of the prepared ME. The cytotoxicity of ME was interpreted by 
calculating the percentage of viable cells after interaction with the 
ME formulation and its individual components. The cytotoxicity of 
ME was illustrated by the decline in cellular viability of lymphocytes 
in a dose-dependent manner (fig. 8). The contact of ME with the 
human lymphocytes have the ability to impair the functional role of 
mitochondria, and the cytotoxicity was generally due to the 
initiation of cell death through the mitochondrial-dependent 
pathway [47]. The cytotoxicity study done on human lymphocytes 
displays that the ME at lower concentration (<25%) shows lesser 
toxicity to the cells compared to the higher concentrations, showing 
more than 50% of viable cells. This result confirms that the LG oil 
with acidic pH was not found to be highly toxic to lymphocytes at a 
lower concentration. In ME, an aqueous solution (water) takes the 
major portion with only 5% of LG oil. LGME-AZM prepared with the 
maximum solubility of the drug in LG oil, and the toxicity testing 
determines lesser toxicity compared to the control. This confirms 
the intake of LG oil based ME to be orally safe in ME form. 
 
 
Fig. 8: Cytotoxicity estimation for the cellular viability of human lymphocytes by MTT assay 
 
(b) In vivo acute and sub-acute toxicity testing 
Male Wistar rats were used for in vivo toxicity assessment. From the 
results obtained from all experimental group along with the healthy 
control, there were no abnormalities observed in physical 
appearances such as scabies, mucoid or soft stool, hair loss, soft or 
mucoid stool, and decreased defecation. During the experimental 
process, the initial and final body weight of all the animals showed 
no abnormal variations. The enzyme activities of liver and kidney 
parameters were estimated from the blood collected, and the result 
determines that the values were similar as that of the healthy group 
of Wistar rats, as shown in table 5. Haematological parameters 
showed no abnormalities compared with the healthy control, as 
shown in table 6. Histopathological evaluation of liver and small 
intestine samples after consumption of microemulsion comprise to 
control group did not show any major abnormalities in organs and 
tissues. The dosage groups and the healthy group showed normal 
parenchymal structures with cords of hepatocytes observed with no 
major changes when compared to the normal control group. This 
confirms that the ME dosage group of animals showed no changes in 
structural and histopathological properties in small intestine and 
liver (fig. 9) compared to the normal healthy rats. 
 
 
Fig. 9: In vivo toxicity testing. H and E stained section of small intestine (Top) and liver (bottom) of three animal groups: Normal Controls 
treated with saline (A1, A2), dosage groups treated with LGME system (B1, B2), and dosage groups treated with LGME-AZM (C1, C2). 
(Magnification at 400X). Cellular morphology was observed with no abnormalities as marked: 1-Simple columnar epithelium, 2-
Cytoplasm of goblet cells-mucin containing secretory vesicles, 3-Hepatocytes, 4-Central lobular vein 
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Table 5: Biochemical parameters in wistar rats 
Groups ALT (IU/l) AST (IU/l) Creatinine (mg/dl) 
Control 30.11±3.24 79.19±9.28 0.41±0.02 
LGME system 32.14±2.79 78.34±11.32 0.42±0.02 
LGME-AZM 33.26±3.36 77.5±9.78 0.38±0.02 
(ALT-Alanine transaminase, AST-Aspartate transaminase; *
 
Values with mean±SD n = 6)  
Table 6: Hematological parameters in Wistar rats 
Groups Hb (gm%) Total WBC count (cells/cu. mm) RBC count (millions/cu. mm) Platelets count (lakhs/cu. mm) 
Control 18.2±0.16 8900±101.98 6.02±0.05 2.61±0.01 
LGME system 17.1±0.24 10103±81.78 5.70±0.08 2.44±0.04 
LGME-AZM 17.3±0.09 8303±68.4 5.73±0.16 2.14±0.09 
(Hb-Hemoglobin, WBC-White blood cell, RBC-Red blood cell; *
 
Values with mean±SD n = 6) 
CONCLUSION 
The current work describes a lemongrass oil–based microemulsion 
system with azithromycin (LGME-AZM), formulated with low-energy 
methods, to obtain small droplets of uniform size, minimum surfactant 
concentration, and good thermodynamic stability for pharmaceutical 
application as a drug delivery vehicle to treat bacterial infections 
against microorganisms. The LG oil ME possesses potent anti-bacterial 
activity, which makes it a safer system for solubilizing hydrophobic 
antimicrobial drugs to enhance its antibacterial activity, thus paving 
the way to limit high drug dosage concentration. Toxicity studies 
confirm the optimized ME to be safer for oral intake, and thus this 
paves the major impact as an oral drug delivery system by increasing 
the efficacy of the lipophilic drug. 
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